TrialLancet (London, England)2017

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.

John P Neoptolemos et al.PubMed ↗Publisher ↗

No numbers read from the abstract.